ArticleScientific reports2025
Integrative analysis of pancreatic microbiota and metabolome in patients with pancreatic ductal adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Modern Approaches to Diagnosis and Evaluation of Survival Prognosis in Patients with Pancreatic Cancer.International journal of molecular sciences · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The importance of microbiota-associated metabolites in pancreatic ductal adenocarcinoma (PDAC) tumorigenesis highlights the need to investigate the microbiota and metabolome along the normal-adjacent-carcinoma sequence to explore their mechanistic implications in PDAC tumorigenesis. We characterized the pancreatic microbiota and metabolome in four distinct tissue groups using 16S rRNA amplicon sequencing and untargeted metabolomics: tumor tissues from 23 PDAC patients (PDAC T), their matched para-carcinoma tissues (PCT), tumor tissues from 13 pancreatic benign tumor patients (Control T), and their matched non-tumor tissues (Control N). For the selected metabolites, we verified their functional activities using cell proliferation assay. From Control N, through PCT, to PDAC T, there were 90 significantly differential genera, of which seven genera increased and 65 genera decreased sequentially. Specifically, Peptostreptococcus, norank_f__Mitochondria, and Ileibacterium increased, while Faecalibacterium, Ruminococcus, Subdoligranulum, and Coprococcus decreased sequentially. Among altered metabolites, beta-guanidinopropionic acid (GPA), S-(2-Carboxyethyl)-L-cysteine, L-lactic acid, and 3-hydroxybutanoic acid increased, while (3Z)-2-Propylpent-3-enoic acid, linoleic acid, and monopalmitin decreased sequentially. PDAC-associated metabolites were enriched in the GABAergic synapse, butanoate metabolism, purine metabolism, and CCM in cancer pathways. GPA and S-(2-Carboxyethyl)-L-cysteine were also enriched in the chemotherapy-resistant patients compared with chemotherapy-sensitive patients, while Faecalibacterium and (3Z)-2-Propylpent-3-enoic acid were also reduced. In both PDAC tumorigenesis and chemotherapy-resistant patients, decreased Faecalibacterium was positively correlated with (3Z)-2-Propylpent-3-enoic acid, but negatively correlated with GPA and S-(2-carboxyethyl)-L-cysteine. CCK8 assays confirmed that GPA and S-(2-carboxyethyl)-L-cysteine promoted the proliferation of PDAC cell lines. GPA and S-(2-Carboxyethyl)-L-cysteine were enriched in both PDAC tumorigenesis and chemotherapy-resistant patients, while Faecalibacterium and (3Z)-2-Propylpent-3-enoic acid were reduced. GPA and S-(2-carboxyethyl)-L-cysteine could promote the proliferation of PDAC cell lines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.